Extended adjuvant treatment of early breast cancer in postmenopausal women who have received 5 yr of adjuvant tamoxifen therapy. 1st-line treatment of postmenopausal women w/ hormone receptor +ve or unknown locally advanced, or metastatic breast cancer. Advanced breast cancer in postmenopausal women w/ disease progression following anti-estrogen therapy.
View Letvex overdosage for action to be taken in the event of an overdose.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity. Pre-op use if the receptor status is -ve or unknown. Severe hepatic impairment (Child-Pugh grade C). Premenopausal women. Pregnancy & lactation.
Assess & initiate treatment for bone mineral density of women w/ or at risk of osteoporosis. Patients w/ CrCl <10 mL/min. Not for use in men w/ breast cancer. Hepatic &/or renal impairment. Not recommended for childn.
Sign Out
